Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 8/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971351 | 1.00 | BTN3A1 (0.41) | BTN3A1LMNAELANEPRTN3ANPEP | |
| SCHEMBL7027815 | 0.90 | PRTN3 (0.39) | BTN3A1LMNAELANEPRTN3ANPEP | |
| SCHEMBL1809936 | 0.89 | CA1 (0.40) | LMNAL3MBTL1 | |
| SCHEMBL3970115 | 0.88 | TSHR (0.39) | BTN3A1ELANEPRTN3L3MBTL1 | |
| SCHEMBL3970116 | 0.88 | TSHR (0.39) | BTN3A1ELANEPRTN3L3MBTL1 | |
| SCHEMBL857081 | 0.88 | ELANE (0.48) | ELANEPRTN3F2PLAUPLAT | |
| SCHEMBL1809147 | 0.88 | HPGD (0.42) | — | |
| SCHEMBL7022520 | 0.87 | NPC1 (0.38) | LMNAPRTN3 | |
| SCHEMBL7024859 | 0.86 | FAAH (0.39) | LMNA | |
| SCHEMBL7026839 | 0.85 | ELANE (0.41) | ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904365-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2022-09-07 | — | — | EP | disclosed |
| EP-3904365-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2021-11-03 | — | — | EP | disclosed |
| US-20210130387-A1 | PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AS ANTICANCER AGENTS | NuCana plc (GB) | 2021-05-06 | — | — | US | disclosed |
| US-10906929-B2 | Phosphoramidate nucleoside derivatives as anticancer agents | NuCana plc (GB) | 2021-02-02 | — | — | US | disclosed |
| EP-3464309-B1 | PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AS ANTICANCER AGENTS | NuCana plc (GB) | 2020-06-10 | — | — | EP | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3486251-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2019-05-22 | — | — | EP | disclosed |
| EP-3150608-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3464309-A1 | PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AS ANTICANCER AGENTS | Nucana PLC (GB) | 2019-04-10 | — | — | EP | disclosed |
| EP-3040340-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-11-14 | — | — | EP | disclosed |
| US-7115590-B1 | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R, cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2006-10-03 | — | — | US | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
| US-6638919-B2 | Aids therapy | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2003-10-28 | — | — | US | disclosed |
| EP-1150988-B1 | PHOSPHORAMIDATE, AND MONO-, DI-, AND TRI-PHOSPHATE ESTERS OF (1R, CIS)-4-(6-AMINO-9H-PURIN-9-YL)-2-CYCLOPENTENE-1-METHANOL AS ANTIVIRAL AGENTS | GLAXO GROUP LTD (GB) | 2003-05-28 | — | — | EP | disclosed |
| EP-1117669-B1 | ANTIVIRAL PURINE DERIVATIVES | UNIV CARDIFF (GB) | 2003-01-29 | — | — | EP | disclosed |
| US-20010031745-A1 | Antiviral purine derivatives | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-10-18 | — | — | US | disclosed |
| EP-1117669-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD. (GB) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018775-A1 | ANTIVIRAL PURINE DERIVATIVES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906929-B2 | Phosphoramidate nucleoside derivatives as anticancer agents | PNP, TYMP, MTAP | BTN3A1 3612/4885LMNA 4161/4885ELANE 3416/4885 |
| US-20210130387-A1 | PHOSPHORAMIDATE NUCLEOSIDE DERIVATIVES AS ANTICANCER AGENTS | PNP, MTAP, NUDT1 | BTN3A1 3309/4885LMNA 4185/4885ELANE 3252/4885 |
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | BTN3A1 3438/4885LMNA 2434/4885ELANE 3975/4885 |
| US-20010031745-A1 | Antiviral purine derivatives | PNP, TYMP, MTAP | BTN3A1 2779/4885LMNA 898/4885ELANE 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.